Instructions to Authors

I. Editorial Policy

The Chinese Pharmaceutical Journal publishes studies on all the disciplines of the pharmaceutical sciences. Research areas covered in the journal include bioanalytical chemistry and pharmaceutical dosage form analysis, bioavailability and bioequivalence studies, drug metabolism, medicinal chemistry and pharmacognosy, novel dosage forms and drug delivery systems, physical pharmacy and pharmaceutical technology, pharmacology and pharmacodynamics, pharmacokinetics, toxicology, clinical pharmacy, pharmaceutical care, pharmacoeconomics, pharmacogenetics, pharmacotherapy, pharmacy administration and the field of biotechnology which has yielded promising new drugs.

It provides a medium for publication of original research articles, notes, communications or reviews. Articles are definitive, full accounts of significant studies. Notes should be concise accounts of studies whose scope is more limited than that of articles. Short communication that reports new findings of outstanding importance will be published promptly after review and acceptance. Reviews are generally invited and reported on subjects of current interests in all aspects of pharmaceutical sciences.

All manuscripts will be refereed by at least two experts in the research area of the paper. When revision is necessary, the manuscript with the comments of the referees is returned to the authors. Revised manuscripts must be resubmitted to the corresponding senior editor in duplicate with all pages affected by retyping. If English is not the author's native language, the manuscript will be checked by English editor before publishing and the fee will go to the corresponding author. The final decision on any manuscript rests with the editor.

Submission of manuscripts to The Chinese Pharmaceutical Journal implies that they represent original research not previously published (except in the form of an abstract or preliminary report) and they are not being considered for publication elsewhere in the same form, in any language, without the consent of the editor. By accepting a manuscript the journal acquires all rights, in particular copyright and the rights of translation.

II. Submission of Manuscripts

Manuscripts, in **triplicate** and in **English**, should be submitted to the Editor-in-Chief:
Prof. An-Rong Lee, PhD, School of Pharmacy, National Defense Medical Center, 161, Minchuan East Road, Sec. 6, Taipei 114, Taiwan, Republic of China; Tel: 886-2-8792-3100 ext. 18181; Fax: 886-2-8792-3169; Website: http://www.pharm.org.tw/
Manuscript should be printed, double spaced, one side only, on 22 × 28 cm (8.5 × 11 inch) or A4 paper with 2.54 cm (1 inch) margins on all sides. Each copy must include all tables, figures, structures, and schemes. The original manuscript should include the camera-ready copies of the figures, structural formulas, and schemes; these should be placed at the end. Authors should indicate by text where the tables, figures, structures, and schemes are to be inserted. Separate sheets should be used for the title page, with authors' names and affiliations, and for the abstract. All pages should be numbered consecutively, starting with the title page and continued in the following order: text, references, tables, figures, legends, structures and schemes.

(a) The **title** should reflect the purposes and findings of the work in order to provide maximum information in a computerized title search. Titles should be followed by the authors' full names and by the addresses of all contributing laboratories. The name of the corresponding author should be marked with an asterisk (*), and his e-mail address and fax number be given, if available, for rapid communication.

(b) Every manuscript must include an abstract (80-200 words) describing briefly and clearly the purpose of the research, results and conclusions. A maximum of 6 key words and 50 letters (including space) of the running title followed the abstract must be provided by the authors.

(c) The manuscript can be organized under headings such as **INTRODUCTION, RESULTS, DISCUSSION** (or **RESULTS AND DISCUSSION**), and **EXPERIMENTAL SECTION.** or **INTRODUCTION, MATERIALS AND METHODS, RESULTS, DISCUSSION** (or **RESULTS AND DISCUSSION**).

(d) **Tables.** Tables should be numbered consecutively in order of citation in the text with Arabic numerals. Footnotes in tables should be given lower case letter designations and cited in the tables as superscripts. Each table should be typed on a separate sheet of paper and must be provided with a descriptive heading.

(e) **Figures.** Figures should be numbered consecutively with Arabic numerals and should appear on separate pages. Legends for figures should appear together as a block. Blocks of structural formulas should not be designated as figures but may be represented as schemes or charts.

(f) **Structural Formulas.** Structural formulas must be drawn clearly and should be used with a view to the most economical use of space consistent with clarity. All structures should be numbered with Arabic numerals. For authors using the ChemDraw program, the following preference items are recommended: fixed length, 18 point; line width, 0.8 point; bold width, 2.5 point; hash spacing, 3.0 point; margin width, 2.0 point; bond spacing, 18% of length. Single-width bold and dashed lines are preferred to wedges for stereochemical notations; 12-point Helvetica font should be used, for both atom labels and text materials. Drawings should be prepared with the page setup at 80% and printed in this manner with a laser printer on good quality white paper, preferably 25% rag bond.

(g) **Software.** Software used as a part of computer-aided drug design (e.g., molecular modeling, QSAR, etc.) should be readily available from reliable sources, and the authors should specify where the software can be obtained.

(h) **Nomenclature.** It is the responsibility of the authors to provide correct nomenclature. All nomenclature must be consistent and unambiguous and, insofar as is practical, should conform with the Rules of Nomenclature established by the International Union of Pure and Applied Chemistry (IUPAC), the International Union of Biochemistry (*Europ. J. Biochem.*, **1977,** *74,* 1), the Chemical Abstracts Service (CAS), and other appropriate bodies.

(i) **X-ray Data.** The results and analysis should include (1) unit cell parameters and standard error; (2) the formula, formula weight, and number of formula units in the unit cell; (3) measured and calculated densities; (4) space group; (5) wavelength used, number of

reflections observed, and (for diffractometer data) number of unobservedly weak reflections; (6) method of collection of intensity data and methods of structure solution and refinement; (7) final R values; (8) statement on the presence or absence of significant features on a final difference Fourier map; (9) noteworthy bond lengths and angles; (10) a clear representation of the structure; and (11) tables (with standard deviations) of (a) final atomic positional parameters, (b) atomic thermal parameters, and (c) bond distances and angles. Items 1-11 should be submitted for the printed edition (items 1-8 in the Experimental Section).

(j) **References and Notes.** Literature references and notes should be numbered in one consecutive series by order of appearance in the text, with numbers as unparenthesized superscripts. The complete list of references and notes should be typed double-spaced on separate page(s) at the end of the manuscript using the following format.

For Journals: Meade, E. A.; Wotring, L. L.; Drach, J. C.; Townsend, L. B. Synthesis, Antiproliferative, and Antiviral Activity of Certain 4-Aminopyrrolo[2,3-*d*]pyridazine Nucleosides: An Entry into a Novel Series of Adenosine Analogues. *J. Med. Chem.* **1992,** *35,* 526-533.

For Monographs: Casy, A. F.; Parfitt, R. T. Opioid Analgesics; Plenum Press: New York, 1986; pp 333-384.

For Edited Books: Rall, T. W.; Schleifer, L. S. Drugs Effective in the Therapy of the Epilepsies. in The Pharmacological Basis of the Therapeutics, 7th ed.; Gilman, A. G., Goodman, L. S., Rall, T. W., Murad, F., Eds.; Macmillan Publishing Co.: New York, 1985; pp 446-472.

For Theses: Wang, H.-P. Synthesis of Dihydrothioxanthenedione Analogs as Potential Antimalarial Agents. Ph.D. Thesis; The University of Michigan, Ann Arbor, MI, USA, 1982.

For Patents: Chern, J.-W.; Shiau, C.-Y.; Yen, M.-H.; Lu, G.-Y. 2-Substituted Methyl-2,3-dihydroimidazo[1,2-*c*]quinazolin-5(6*H*)-ones(-thiones), the Preparation and Use thereof. U.S. Patent 5, 158,953, 1992; *Chem. Abstr.* **1993**, *118*, 169114f.

Submitted manuscripts should be cited as "in press" only if they have been officially accepted for publication after the journal, volume, and year; otherwise, use "unpublished results" after the names of authors.

(k) **Abbreviations.** Standard abbreviations should be used as given in the *ACS Style Guide*. Please note that these are used in this Journal without periods. The preferred forms for some of the more commonly used abbreviations are mp, bp, °C, K, min, h, mL, μL, g, mg, μg, cm, mm, nm, mol, mmol, μmol, ppm, TLC, IR, UV, NMR, and MS *m/z*. In the interest of space economy, compounds should be given a bold-face (or underlined) number when first mentioned, and referred to by this number throughout the ensuing text.

(l) **Physical, Chemical Data and Analyses. Optical rotation** data should be presented in the established form, viz. $[\alpha]_D + 40$ (MeOH; c = 1.0). **Mass spectral** data must indicate the method used (EIMS, CIMS, FABMS, SIMS). The data should give only the diagnostically important ions, the character of the fragmentation ions in relation to the molecular ion and the intensity relative to the major ion. For example, EIMS *m/z* (rel. int): 396 $[M]^+$ (36), 378 $[M\text{-}H_2O]^+$ (100), 363 $[M\text{-}H_2O\text{-}Me]^+$ (23). **Visible** and **ultraviolet spectral** data should be presented in the established form viz. UV λ_{max} nm (MeOH) (log ε): 224 (4.57) 250 (3.21); UV λ_{max} nm (MeOH + 0.1% NaOH) (log ε): 320 (4.22); UV λ_{max} nm (MeOH + $AlCl_3$) (log ε): 275 (4.49). **Infrared spectral** data should be presented in the established form, viz. IR (KBr) cm^{-1}: 3500 (-OH), 1740 (>C=O). **NMR spectral** data must be specified as ^1H NMR and/or ^{13}C NMR and should indicate the frequency of the instrument used, the solvent used and the internal standard. Chemical shifts should be quoted in δ units related to TMS with indication of whether the signal is a singlet *s*, duoblet *d*, doublet of doublets *dd*, triplet *t* or multiplet *m*. ^{13}C NMR data should specify the carbon concerned, using the recommended IUPAC numbering (e.g. C-1, C-2), and should be given to one decimal place. ^1H NMR data should indicate the number of hydrogens involved and their position of attachment based on the numbering of the carbon atoms, preferably according to IUPAC rules. For example, ^1H NMR (100 MHz, $CDCl_3$): δ 0.52 (3H, *s*, H-18), 0.86 (6H, *d*, J = 6 Hz, H-26 and H-27), 0.97 (3H, *t*, J = 5 Hz, H-21), 4.34 (1H, *q*, $J_{6\alpha,7\alpha}$ = 4.5 Hz, $J_{6\alpha,7\beta}$ = 2 Hz, H-6), 4.28 (1H, *m*, $W_{1/2}$ = 18 Hz, H-3α). ^{13}C NMR (25 MHz, $CDCl_3$): δ 10.5 (C-5), 74.2 (C-6), 123.7 (C-3). **Elemental analyses** that agree with calculated values within 0.4% should only be reported as in the following example: Anal. Calcd for $C_{13}H_{23}NO_{12}$: C, 40.52; H, 6.02; N, 3.64. Found: C, 40.32; H, 5.97; N, 3.56.

(m)**Typesetting from Disks.**

To expedite publication, *Chinese Pharmaceutical Journal* is now copy editing accepted manuscripts electronically. When submitting revised manuscripts, authors are encouraged to send a disk of the paper along with required three hard copy printouts. If the manuscript is accepted, the disk, with the printout as backup, will be sent to **Printing Office**, where the article will then be copy edited on-line and typeset from disk. The disk should contain all the parts of the manuscript on one file. However, tables and mathematical material, such as equations, may be excluded from the disk file because they must still be copy edited and typeset in the traditional manner from the accompanying hard copy.

Please label the outside of the disk with *Chinese Pharmaceutical Journal*, the first author's name, a partial title of the manuscript, and the name of the computer file used to assess the manuscript on the disk. In addition, we will need to know the name of the computer used (e.g., IBM/PS2), the name of the operating system and version (e.g., Word 97), and the word processing program and version (e.g., WordPerfect 6.0). We prefer following word processing programs, XyWrite III Plus (for the IBM), WordPerfect (for the IBM and for the Mac), Microsoft Word (for the IBM and for the Mac), Amipro (for the IBM), and Wordstar (for the IBM). If your program is not listed herein, send in your disk and we will attempt to typeset from it.

III. Proofs and Reprints

(a) Proofs will be sent to the corresponding author indicated on the title page. They should be carefully corrected and returned to the **Printing Office** as soon as possible, within 48 h at most. An order form for reprints will accompany the proofs and should be returned to the **Printing Office** with the corrected proofs. Request of the cover page of the reprints will be charged.

(b) The journal has no page charges. Reprints in multiples of a fifty may be purchased on a reprint order form which will accompany the proofs. Reprints will be sent to the corresponding author.